Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) × VGX-3100 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Intraepithelial Lesions 4 Uterine Cervical Neoplasms 2 Uterine Cervical Dysplasia 2 Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1 Papillomavirus Infections 1 Head and Neck Squamous Cell Cancer 1 HIV Seropositivity 1 Anus Neoplasms 1

Interventions

VGX-3100 1 Imiquimod 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03180684 2023-08-25

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Inovio Pharmaceuticals

Phase 2 Completed

33 enrolled 19 charts

Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡